| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5657523 | Clinical Gastroenterology and Hepatology | 2017 | 42 Pages |
Abstract
In an analysis of data from 4 phase 3 clinical trials, we found that patients with HCV infection (especially those with decompensated cirrhosis) have significant increases in their PRO scores during treatment with sofosbuvir and velpatasvir and after achieving a sustained virologic response.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Zobair M. Younossi, Maria Stepanova, Jordan Feld, Stefan Zeuzem, Mark Sulkowski, Graham R. Foster, Alessandra Mangia, Michael Charlton, Jacqueline G. O'Leary, Michael P. Curry, Fatema Nader, Linda Henry, Sharon Hunt,